CHMP positive opinion for Xultophy?

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use under the European Medicines Agency has adopted a positive opinion for Xultophy, the first-ever once-daily basal insulin (insulin degludec, Tresiba)
and GLP-1 analogue (liraglutide, Victoza) in one pen.

Source: Pharmacy Europe - July 28, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Diabetes Featured Articles Tresiba Xultophy Source Type: news